Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675637 | 0.85 | MAPT (0.45) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| SCHEMBL5195730 | 0.85 | MAPT (0.45) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| SCHEMBL17077586 | 0.84 | TSHR (0.53) | ALDH1A1KDM4EGAAHSD17B10TSHR | |
| SCHEMBL16952618 | 0.83 | TSHR (0.44) | ALDH1A1KDM4EGAAHSD17B10TSHR | |
| SCHEMBL181067 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAAHSD17B10TSHR | |
| SCHEMBL7489211 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAAHSD17B10TSHR | |
| SCHEMBL3511611 | 0.82 | TSHR (0.57) | ALDH1A1KDM4EGAAHSD17B10TSHR | |
| SCHEMBL20436373 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAHSD17B10TSHR | |
| SCHEMBL646271 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAHSD17B10TSHR | |
| SCHEMBL14050225 | 0.81 | ALDH1A1 (0.52) | ALDH1A1KDM4EGAAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1324992-B1 | CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1324992-B1 | CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| US-20050192318-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | US | disclosed |
| US-6924277-B2 | Cyclized benzamide neurokinin antagonists for use in therapy | ASTRAZENECA AB (SE) | 2005-08-02 | — | — | US | disclosed |
| US-20040029850-A1 | Cyclized benzamide neurokinin antagonists for use in therapy | ASTRA ZENECA AB (SE) | 2004-02-12 | — | — | US | disclosed |
| EP-1324992-A1 | CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY | AstraZeneca AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026724-A1 | CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | ALDH1A1 1904/4885KDM4E 1401/4885GAA 1028/4885 |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | UPF1, RIOX2, RNMT | ALDH1A1 1460/4885KDM4E 1290/4885GAA 582/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | ALDH1A1 1904/4885KDM4E 1401/4885GAA 1028/4885 |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | ALDH1A1 959/4885KDM4E 1881/4885GAA 579/4885 |
| US-20050192318-A1 | Compounds | PCSK9, CYP11B2, CYP27A1 | ALDH1A1 1381/4885KDM4E 4125/4885GAA 23/4885 |
| US-20040029850-A1 | Cyclized benzamide neurokinin antagonists for use in therapy | BDKRB1, BDKRB2, NPY1R | ALDH1A1 2186/4885KDM4E 3742/4885GAA 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.